Filing Flows › Comparisons › REGN vs VRTX
Regeneron Pharmaceuticals vs Vertex Pharmaceuticals: REGN and VRTX compared
Regeneron Pharmaceuticals is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $3.4B for Vertex Pharmaceuticals (Q3 2026). Regeneron Pharmaceuticals is growing faster (+36% against +12% a year earlier). Regeneron Pharmaceuticals is more profitable, with an operating margin of 40.0% against 20.7%.
Where the money goes: REGN and VRTX
Regeneron Pharmaceuticals (REGN) · Q3 2026
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Vertex Pharmaceuticals (VRTX) · Q3 2026
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $5.1B | $3.4B |
| Revenue growth, Y/Y | +36% | +12% |
| Operating margin | 40.0% | 20.7% |
| Net earnings | $1.9B | $654M |
| Net margin | 38.1% | 19.0% |
| Operating cash flow | $1.8B | $643M |
| Free cash flow | $1.5B | $546M |
| Market value | $95.3B | $139.6B |
| P/E | 20.0× | 35.2× |
| Analysts’ mean target | $977.93 | $592.36 |
Where the revenue comes from
Regeneron Pharmaceuticals
- Collaboration revenue: $3.0B (59%)
- Net product sales: $1.8B (35%)
- Other revenue: $310M (6%)
- Lynozyfic: $19.0M (0%)
Vertex Pharmaceuticals
- Total CF product revenues, net: $3.3B (95%)
- CASGEVY: $99.2M (3%)
- JOURNAVX: $58.3M (2%)
Questions
Which is bigger, Regeneron Pharmaceuticals or Vertex Pharmaceuticals?
Regeneron Pharmaceuticals is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $3.4B for Vertex Pharmaceuticals (Q3 2026).
Is Regeneron Pharmaceuticals or Vertex Pharmaceuticals growing faster?
Regeneron Pharmaceuticals is growing faster (+36% against +12% a year earlier).
Which is more profitable, Regeneron Pharmaceuticals or Vertex Pharmaceuticals?
Regeneron Pharmaceuticals is more profitable, with an operating margin of 40.0% against 20.7%.
More: Regeneron Pharmaceuticals earnings · how Regeneron Pharmaceuticals makes money · Vertex Pharmaceuticals earnings · how Vertex Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.